Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

This trial is a prospective clinical trial designed to demonstrate the safety and feasibility of whole-pelvis adaptive prostate stereotactic body radiation therapy (SBRT) with a tumor boost to the magnetic resonance (MR)-detected sites of disease. The hypothesis is that this treatment approach will be safe and feasible with \<15% of patients experiencing an acute CTCAEv5 grade ≥3 genitourinary (GU) or gastrointestinal (GI) adverse event.

NCT Number	NCT05628363
Lead Sponsor	Washington University School of Medicine Collaborators: Varian Medical Systems
Conditions	Prostate Cancer, Cancer of the Prostate
Enrollment	28 participants
Start Date	2023-01-18
Primary Completion	2025-10-25 (estimated)
Study Completion	2030-07-25 (estimated)
Updated on ClinicalTrials.gov	2026-07-02